Nachrichten zur Pfizer Inc. Aktie

AbbVie and Pfizer Have 1 Thing in Common: Their Biggest Products Are on the Decline. Time to Sell?

Both companies share prices have slipped recently.…

AbbVie and Pfizer Have 1 Thing in Common: Their Biggest Products Are on the Decline. Time to Sell? @themotleyfool #stocks $ABBV $PFE

Both companies share prices have slipped recently.…

Pfizers (PFE) New Products May Drive Long-Term Sales Growth

Though Pfizers (PFE) revenues from COVID products are declining sharply, the launch of some key non-COVID products in 2023 is…

Eli Lillys Olumiant and Pfizers Litfulo Strengthen Alopecia Areata Arsenal, Yet Resounding Opportunity for JAK Expansion and New Assets in Development Remain

Despite little prescriber differentiation between the JAKs, including satisfaction and manufacturer perceptions, Olumiant is projected to maintain a significant market…

Pfizer to halve UK workforce at Discovery Park

Pfizer Inc (NYSE:PFE) has said it will lay off more than half of its employees at a UK-based scientific research centre…

Pfizer: Victim Of Vaccine Side Effects

…

Pfizer to shed 500 jobs at England site as cost-cutting ramps up

…

Pfizer to cut 500 jobs at Kent site

Pfizer is cutting 500 jobs at its Sandwich, Kent site in the U.K. as part of a cost-cutting effort, Sky…

Pfizer to cut 500 jobs at Kent site - Sky News By Reuters

Pfizer to cut 500 jobs at Kent site - Sky News…

Better Growth Stock: Pfizer vs. Novo Nordisk

One is growing now, and the other will grow soon.…

Top Analyst Reports for Meta Platforms, Walmart & Pfizer

Todays Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Walmart Inc. (WMT) and…

Pfizer Stock Hits 3-Year Low—Down 50% From 2021 Peak

Excluding a brief early 2020 plunge, Pfizer shares are now trading at their lowest level since 2016.…

US Gastroenterologist Projections Suggest Significant Shift in Ulcerative Colitis Landscape Afoot, with Launches of Eli Lillys Omvoh, Pfizers Velsipity, Takedas Subcutaneous Entyvio, and Celltrions Zymfentra

Prior to launch, prescribers estimate that TNF inhibitors are likely to bear the greatest brunt of increased adoption of the…

Opening Bell: US-Investoren vor Inflationsdaten an der Seitenlinie; Pfizer, AMD, Palo Alto Networks, Dell, Waste Management im Fokus

Am Freitag noch im Rally-Modus, zum Wochenauftakt an der Seitenlinie: Die US-Investoren üben sich am Montag in Zurückhaltung. In der…

Pfizer wants in on the weight loss drug market – and upcoming data will be crucial for its success

Analysts said upcoming data on Pfizers obesity pill, danuglipron, will be crucial to how competitive the company can be against…

Eilt: Biotech Hot Stock unmittelbar vor globalem Lizenzdeal. Neuer 384% Biotech Aktientip nach 10.996% mit Pfizer ($PFE)

Calgary (www.aktiencheck.de, Anzeige) Einschätzung Strong OutperformerKurszieleKursziel 12M: 9 USD Kurschance: 223% Kursziel 24M: 13,50 USD Kurschance: 384%StammdatenISIN: CA98420Q3061 WKN: A3EUNZ Ticker: ANUA TSXV: XRTX.V NASDAQ: XRTXKursdatenKurs: 2,79 USD 52W Hoch:…

Pfizer Inc. (PFE) Presents at Truist Securities BioPharma Symposium (Transcript)

…

ACHV: Ancillary Studies Complete

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported third quarter 2023 results in a…

Pfizer may file substantial compliance with FTC on Seagen in 3-4 weeks - CNBC

…

Zacks Earnings Trends Highlights: Pfizer, Eli Lilly, General Motors and Tesla

Pfizer, Eli Lilly, General Motors and Tesla have been highlighted in this Earnings Trends article.…

: Syphilis cases among newborns are skyrocketing, CDC says

Pfizer works to speed production of key penicillin as officials see "unacceptable American crisis," underscoring need for rapid testing and…

Pfizer to Cut $3.5B in Costs, Close NJ Plant

…

PLX: More Regulatory Approvals

By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Third Quarter 2023 Financial and Operational Review Protalix Biotherapeutics, Inc. (NYSE:PLX) announced 3Q:23…

BioNTech Earnings Beat. Pfizer’s Vaccine Partner Battles Covid Downturn.

…

ROUNDUP: Biontech erwartet weniger Umsatz mit Corona-Impfstoff

MAINZ (dpa-AFX) - Das Biotechnologieunternehmen Biontech hat wie andere Hersteller mit dem schrumpfenden Absatz von Covid-19-Impfstoffen zu kämpfen. Die…

: BioNTech’s stock rallies after it posts surprise Q3 profit and revenue that tops estimates

BioNTech SE’s stock BNTX rallied premarket after the company posted a surprise profit for the third quarter and revenue that…

Pfizer: Hohe Kosten, schwächelnde Pipeline und Rückgang der COVID-19-Umsätze - Aktienanalyse

Wien (www.aktiencheck.de) - Pfizer-Aktienanalyse von der Raiffeisen Bank International AG: Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), rät in…

BioNTech und Bayer unter Druck - Defence Therapeutics dagegen mit guten Resultaten. Wo lohnt der Einstieg?

Derzeit gibt es in der Pharma- und Biotechbranche große Verlierer unter den Unternehmen, welche die größten Profiteure der Corona Krise…

Sosei Heptares’ Partner, Pfizer, Progresses Its GLP-1 Receptor Agonist PF-06954522 into a Phase 1 Trial

Tokyo, Japan and Cambridge, UK, 06 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) has…

Did Barron’s nail the peak in yields?

The old adage is that magazine covers are a jinx. That’s particularly true with The Economist but Barron’s has had…

Pfizer: Neues Kursziel

London (www.aktiencheck.de) - Rating-Update: Die Analysten von Barclays stufen die Aktie von Pfizer Inc. (ISIN: US7170811035, WKN: 852009, Ticker-Symbol: PFE, NYSE-Symbol:…

Dividend Roundup: ConocoPhillips, IBM, Honeywell, Pfizer, and more

…

Theres a Silver Lining in Pfizers Dark Cloud. Should You Buy the Stock?

Its important to look at Pfizer through a long-term lens.…

Theres a Silver Lining in Pfizers Dark Cloud. Should You Buy the Stock? @themotleyfool #stocks $PFE

Its important to look at Pfizer through a long-term lens.…

Pfizer: Value Investment Opportunity After Recent Price Decline

…

Moderna dampft Umsatzprognose für 2023 ein

New York/Frankfurt (Reuters) - Der US-Biotechkonzern Moderna kappt wegen der schwachen Nachfrage die Umsatzerwartungen für seinen Covid-19-Impfstoff.

Für 2023 rechnet…

Pfizers hair loss drug wins UK authorization

…

Unlike Pfizer, Moderna can meet 2023 COVID forecast, analysts say By Reuters

Unlike Pfizer, Moderna can meet 2023 COVID forecast, analysts say…

Pfizer Posted a Steep Loss. Is It Time to Sell?

A $5.6 billion inventory write-down isnt what investors wanted to see, but this company is made of many moving pieces.…

Pfizer Posted a Steep Loss. Is It Time to Sell? @themotleyfool #stocks $PFE $ABBV

A $5.6 billion inventory write-down isnt what investors wanted to see, but this company is made of many moving pieces.…

Unlike Pfizer, Moderna can meet 2023 COVID forecast, analysts say

Moderna should hit the lower end of its sales target for this year as it only needs to tap a…

1,8 Mrd $ Umsatzpotential - Neuer 402% Biotech Hot Stock nach 10.996% mit Pfizer ($PFE) und 15.973% mit BioNTech ($BNTX)

Calgary (www.aktiencheck.de, Anzeige) Einschätzung Strong OutperformerKurszieleKursziel 12M: 1,00 EUR Kurschance: 234% Kursziel 24M: 1,50 EUR Kurschance: 402%StammdatenISIN: CA98420Q2071 WKN: A3C9TS Ticker: ANU TSXV: XRTX.V NASDAQ: XRTXKursdatenKurs: 0,299 EUR 52W Hoch:…

dpa-AFX ProFeed